ARTICLE
INSIGHT: CARES Act—Tax Deferral Opportunities for Employers
April 29, 2020
Read time: 1 min

ARTICLE
April 29, 2020
Read time: 1 min
ARTICLE / CLIENT ALERT
April 28, 2020
Read time: 8 min
Long-term care facilities, including nursing homes, (collectively, LTCF) have been a hot spot for the transmission of the novel coronavirus disease (COVID-19). In an effort to balance quality, transparency and infection control, on April 24, 2020, the Centers for Medicare & Medicaid Services (CMS) issued a Quality, Safety and Oversight Group (QSO) Memorandum (QSO-20-28-NH) (QSO Memo), which addresses (i) how LTCF quality rating scores will account for COVID-19-related surveys; (ii) CMS’ plans to publish LTCF staffing censuses; and (iii) several frequently asked questions (FAQs) related to prior CMS guidance to LTCFs regarding infection control and operations during the COVID-19 pandemic.
LTCF Quality Surveys
CMS previously announced a suspension of any LTCF surveys except those that focus on urgent patient safety threats and infection-control issues. This targeted focus allowed CMS to prioritize resident safety without interrupting patient care. However, because of CMS’ ongoing targeted inspection plan, the CMS Nursing Home Five Star Quality Rating System could be skewed by over-weighting the ratings of surveyed facilities. CMS will continue posting survey results on the CMS Nursing Home Compare Website, but it will refrain from incorporating targeted survey results into a facility’s star rating. Instead, LTCFs will be scored and rated based on surveys conducted prior to March 4, 2020.
LTCF Staff Censuses
CMS plans to release the average total number of nursing and other staff that each facility has on site per day, recognizing the potential value of this data in assisting state agencies to direct personal protective equipment (PPE) to LTCFs and other healthcare providers. CMS believes this increased transparency may be useful to residents and their families as well as to state and federal public health authorities. This data will also be aggregated by state and nationally. LTCFs are required to report their direct staff census, average daily patient census and total beds to comply with 42 C.F.R. § 483.70(q). However, LTCFs most recently reported this information for the fourth quarter of 2019, meaning the data that will be published may not accurately reflect a facility’s current COVID-19-related staffing.
FAQ Clarifications
In the QSO Memo, CMS addressed 19 FAQs pertaining to its prior guidance and related to certain waivers of federal requirements. Highlights of these FAQs include the following:
Key Takeaways
With increasing focus on LTCFs in the context of the COVID-19 pandemic, CMS guidance to LTCFs continues to evolve while emphasizing fundamental principles of resident health and safety, COVID-19 transmission prevention, and the unique healthcare and psychosocial needs of LTCF residents. LTCFs should consult the QSO Memo FAQs for additional guidance related to particular scenarios relevant to day-to-day operations, and anticipate forthcoming rulemaking on reporting obligations and related matters, as highlighted here.

ARTICLE / CLIENT ALERT
April 28, 2020
Read time: 11 min
Not surprisingly, the COVID-19 pandemic is affecting government review of foreign investment. In the United States, the Committee on Foreign Investment in the United States (“CFIUS”) remains open and continues to review notified transactions, but the effect of staff working remotely is delaying the acceptance of new filings and will likely extend the period of time needed for the review of CFIUS declarations and notifications. The United States has not initiated any substantive changes in its foreign investment review laws or regulations in response to COVID-19, but presumably foreign acquisitions of U.S. health care technology and protective device manufacturers will be given greater scrutiny than they may have received prior to the current pandemic.
In contrast, a number of other countries are responding to the pandemic, and its economic effects on the valuation of companies, by tightening their foreign investment reporting requirements and requiring that transactions that previously were not subject to review now be subject to mandatory reporting and approval processes. In some cases, this merely accelerates the European Union’s goal, announced last year, of having all member states adopt robust foreign investment screening laws by October of this year. In particular, Spain has expanded its foreign investment filing requirements and other EU member states may follow suit. Australia has also expanded filing requirements, while Canada has announced enforcement policy changes that would subject more transactions to stricter scrutiny.
These developments are discussed in further detail below.
On Feb. 13, 2020, the United States enacted final rules implementing the Foreign Investment Risk Review Modernization Act (“FIRRMA”).[1] FIRRMA both expands CFIUS jurisdiction and codifies its recent practices. As a result of the new regulations, CFIUS now requires mandatory reporting of certain acquisitions of U.S. businesses by foreign investors and may, in other cases, initiate review of the national security implications of acquisitions of control by foreign investors of U.S. businesses, certain minority investments and real estate acquisitions. As was previously the case, if CFIUS finds a national security concern, it can seek mitigation, block a pending transaction or force divestiture of completed transactions. It now has the power to impose filing fees and civil penalties for non-filing.
Under CFIUS procedures, filing parties must submit a draft notification or report and wait for CFIUS staff to either accept the filing and begin the waiting period, or return the filing to the parties with a request that the filing be amended to include or clarify certain information. Only when CFIUS staff determines, in its sole discretion, that a filing is acceptable, does the formal review process and timetable begin.
As a result of the COVID-19 pandemic, many CFIUS personnel are working remotely, which means that they do not have access to classified government computer systems necessary for elements of their review. CFIUS staff includes members of the U.S.-intelligence community who support the threat-assessment process. These personnel must work in a security-cleared government office or through secure communications systems.
CFIUS practitioners are reporting that staff is taking longer than usual to accept new CFIUS filings, although it seems to be continuing to process and resolve CFIUS filings made prior to the pandemic. Going forward, it is anticipated that, in addition to delays in acceptance, more CFIUS investigations will be extended into a second 45-day stage in order to provide staff additional review time. Further, for mandatory declarations, more transactions may receive a “no-action” response rather than a formal clearance in to order both expedite review and preserve CFIUS’s ability to investigate more fully, and potentially challenge, closed transactions after the pandemic no longer limits its investigative resources.
Australia’s foreign investment reporting system is one of the strictest among developed countries. The Foreign Acquisitions and Takeovers Act 1975 (“FATA”) requires reporting to the Australian Foreign Investment Review Board (“FIRB”) of an investment by a foreign entity if certain dollar threshold tests are met by the acquired Australian business. Some of the local asset thresholds for reporting are set at zero dollars, although there are also a number of exemptions that may apply.
On March 29, 2020, the Australian Treasurer announced changes designed to help safeguard Australia’s national interest in response to the coronavirus outbreak. According to the regulations published on April 16, 2020[2]:
On April 24, the Australian government issued Guidance Note 53 further explaining the changes.[3] It has also indicated that it “will prioritise urgent applications for investments that protect and support Australian business and Australian jobs.”[4]
On April 18, 2020, the Canadian Minister of Innovation, Science and Industry issued a policy statement declaring that it will subject certain investments by non-Canadian investors to enhanced scrutiny under the Investment Canada Act (“ICA”).[5] The enhanced review applies to investments in Canadian businesses related to “public health” or “critical goods and services.” The reasons given for this stricter review include the declines in value of Canadian businesses and the now-recognized importance of goods and services essential during the COVID-19 pandemic.
Importantly, the new policy does not expand the types of transactions that are subject to mandatory notice under the ICA. Indirect acquisitions of control of Canadian businesses remain excluded from prior approval requirements and will continue to require the filing of a simple post-closing notice. Direct acquisitions of Canadian businesses remain subject to the current thresholds for mandatory filing.
The new policy is likely to result in more thorough review of ICA-notified transactions, and an increase in the number of investigations of non-notifiable transactions initiated under the government’s rights under the ICA to order a national security review of transactions within 45 days after closing, particularly acquisitions of Canadian businesses by state owned enterprises and those involving health care and critical goods and services.
On March 25, 2020, the European Commission issued guidelines “to ensure a strong EU-wide approach to foreign investment screening in a time of public health crisis and related economic vulnerability. The aim is to preserve EU companies and critical assets, notably in areas such as health, medical research, biotechnology and infrastructures that are essential for … security and public order.”[6] In the announcement, EU Commissioner for Trade Phil Hogan said:
“We are facing an unprecedented public health crisis with deep consequences for the European economy … In the current circumstances, we … need to know who invests and for what purpose. The EU and its member states have the right legal tools for that. Today’s guidelines call upon member states to use these tools to the fullest extent and will bring additional clarity on how to use our investment screening framework to prevent a sell-off of strategic EU assets in the current crisis.” [Id.]
The EU does not itself regulate foreign investment, but leaves such review to its member states, 14 of which currently have foreign investment screening mechanisms in place. Under existing EU rules, member states are empowered to screen foreign direct investment from non-EU countries on grounds of security and public order. Protection of public health is recognized as an overriding reason in the general interest. As a result, member states can impose mitigating measures (such as supply commitments to meet national and EU vital needs) or prevent a foreign investor from acquiring or taking control over a company. [Id.]
The EU foreign direct investment screening regulation was adopted in March 2019.[7] It creates an EU-level mechanism to coordinate the screening of foreign investment with its member states. This mechanism will commence Oct. 11, 2020 and may allow for the Commission and member states to issue opinions and comments on specific transactions.
The new Guidelines call on the remaining member states that do not as yet have full screening mechanisms to implement them as promptly as practicable in advance of the October 2020 deadline. Member states are at various stages in the process. France’s new foreign investment review system, which was developed prior to the pandemic, became operative on April 1, 2020. There have been no changes directly related to the pandemic, though it is certain to be a consideration as investments in French businesses are reviewed. On April 23, 2020, the German government held the first reading of a draft bill to amend the German Foreign Trade Act with respect to regulating foreign investment, and its final provisions will presumably will be shaped by the current environment.
On March 17, 2020, the Spanish government approved tightening its regulation of foreign investment under Royal Decree Law 8/2020.[8] This law adds additional reporting obligations to Spain’s existing foreign investment regime. The new rules apply to non-EU/EFTA investors acquiring in excess of 10% or obtaining certain participation in the management of a Spanish company in certain strategic sectors. These strategic sectors mirror those in the U.S. FIRRMA legislation, and include critical technology, critical infrastructure and sensitive personal data.
Under the new rules, prior approval will also be required for any 10% or greater investment or management control in a Spanish company in any sector (i.e., not limited strategic sectors) by (a) a foreign government, including sovereign wealth funds; (b) foreign investors who have already invested in security, public health or public policy sectors in any other EU member state; and (c) foreign investors subject to administrative or judicial proceedings anywhere in the world for engaging in criminal or illegal activities. The new law states that if the proposed investment is not approved within six months, then it is considered prohibited.
Spanish counsel have pointed out that this is an entirely new area of regulation, and many of the law’s terms remain vague and undefined. They will require clarification in order to enable parties to determine whether a particular transaction will require approval by the Spanish authorities prior to implementation.
The Spanish government justifies this increased screening by reference to the COVID-19 pandemic and concerns that decreases in Spanish company valuations may result in foreign investors taking advantage of undervalued Spanish companies, as well as Spain’s desire to comply with the October 2020 EU framework for the screening of foreign investments.
The COVID-19 pandemic has strained government regulators around the world, and the United States is no exception. CFIUS continues to work to review notified transactions but is likely to experience more delays as the pandemic continues.
Around the world, the COVID-19 pandemic may accelerate the prior trend of tightening national regulation of inward foreign investment. In particular, several governments have expressed concern that the economic effects of the pandemic may result in acquisitions of local businesses by foreign investors at depressed values that may harm their national interest. Some governments have responded quickly to this concern, with new regulations being issued with little or no advance warning, although generally the new rules have not been applied to transactions that had already been signed but not closed as of the announcement date. Other countries are likely to follow suit with procedural reporting and policy changes in addressing similar concerns in the coming weeks and months.
Parties negotiating or contemplating cross-border transactions will need to remain vigilant and consult with foreign investment law specialists to carefully monitor the evolving foreign investment regulatory environment during the coming months.
Authored by Peter Jonathan Halasz and Gregory L. Kinzelman.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
[1] 85 FR 3112 (Jan. 17, 2020); and Foreign Investment Risk Review Modernization Act of 2018 (FIRRMA), Subtitle A of Title XVII of Public Law 115–232 (Aug. 13, 2018).
[2] Foreign Acquisitions and Takeovers Amendment (Threshold Test) Regulations 2020, available here (April 16, 2020).
[3] Guidance Note 53: Temporary measures in response to the coronavirus, available here (April 24, 2020).
[4] Q&A — Temporary changes to foreign investment framework, available here (April 17, 2020).
[5] Government of Canada, Policy Statement on Foreign Investment Review and COVID-19, available here (April 18, 2020).
[6] Press Release, Coronavirus: Commission issues guidelines to protect critical European assets and technology in current crisis, available here.
[7] Regulation (EU) 2019/452 of the European Parliament and of the Council as of 19 March 2019 establishing a framework for the screening of foreign direct investments into the Union, available here.
[8] Real Decreto-ley 8/2020, de 17 de marzo, de medidas urgentes extraordinarias para hacer frente al impacto económico y social del COVID-19, available here.
This is a fast-moving topic and the information contained in this Alert is current as of the date it was published.
No user of this information should act or refrain from acting on the basis of information contained herein without seeking legal advice from counsel in the relevant jurisdiction.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

ARTICLE
August 2020
Read time: 3 min
In response to the coronavirus pandemic, our Global Law Firm Network has assembled the COVID-19 Global Guide for Business. The pandemic and the world’s response are constantly evolving. As a result, we have created two volumes of the Global Guide: Responding to the Pandemic and Returning to Work. Download both volumes of this complimentary guide for questions and answers from across Latin America, Europe, the Middle East, Africa, Asia and North America.
Although all nations are fighting a common enemy in COVID-19, governmental responses to the pandemic have differed significantly based on various factors, including local laws, culture and politics, and the degree of severity of the outbreak in each country. Our complimentary Global Guide is designed for multinational businesses, C-level executives, human resources professionals, in-house counsel and anyone who is interested in learning about the world’s response to the COVID-19 pandemic and reopening plans.
The Global Guide includes succinct answers, provided by legal professionals located in more than 50 countries, to important business and employment questions related to government responses to the pandemic and efforts to return to work. The legal professionals who created this guide are members of the McDermott Global Network; without their contributions and continued commitment, this guide would not be possible.
A sample list of questions include:
Volume 1: Responding to the Pandemic
Has your country enacted any special labor or employment measures to deal with COVID-19?
Can employers furlough employees during this COVID-19 health crisis?
Are the federal, state or municipal governments providing any type of economic relief or support for employers and/or employees during this health crisis?
Are employees obligated to disclose to their employer if they have tested positive for COVID-19?
How does the principle of force majeure apply under the applicable contract laws of your country?
What remedies are available to businesses in the event they default with contractual obligations?
Are there any small-business protections available in your country and can the local subsidiary of a foreign entity access them?
Has your country issued any tax amnesty or relief programs because of COVID-19?
Volume 2: Returning to Work
Has your country implemented a reopening plan?
Does your country’s reopening plan include any obligations imposed by the government on employers?

ARTICLE / CLIENT ALERT
April 27, 2020
Read time: 7 min
After receiving approval from the Office of Management and Budget (OMB) on April 23, 2020, the Centers for Medicare and Medicaid Services (CMS) released a survey on April 24, 2020, to collect information on 340B hospitals’ net acquisition costs for 340B-purchased drugs. CMS announced on its Hospital Outpatient Prospective Payment System (OPPS) webpage that the survey is available through May 15, 2020, in spite of requests by hospitals and hospital groups to delay the survey’s implementation because of the Coronavirus (COVID-19) emergency.
CMS indicated that submission of the survey is required for all hospitals that participate in the 340B Program, with the exception of Critical Access Hospitals (CAHs). In addition to a “detailed survey” option that follows previously released data collection instructions, CMS has provided a “quick survey” option to report purchasing at 340B ceiling prices without detailing per-drug acquisition costs. Hospitals should evaluate the risks and benefits of each survey option when deciding which option to complete.
Background
In our previous On the Subject, “CMS Advances 340B Drug Acquisition Cost Survey to OMB and Solicits Final Comments Directly to OMB,” we described a CMS notice signaling that CMS had submitted a proposed survey of hospital 340B drug costs for OMB approval. Now that the survey has been approved by OMB and released by CMS, CMS may use the data to set future reimbursement rates for 340B drugs furnished by hospitals to Medicare beneficiaries.
Since 2018, CMS’s OPPS rules have reduced hospitals’ Medicare Part B reimbursement for 340B drugs from Average Sales Price (ASP) plus 6% to ASP minus 22.5%, a reduction of almost 30%. A federal district court judge struck down the Part B payment reductions in late 2018, in part because CMS did not have sufficient data to support the reductions. While the case is under appeal, CMS has continued to reimburse 340B drugs at ASP minus 22.5%. CMS has indicated that if the appeals court rules against it, CMS will begin basing Part B payments for 340B drugs on “amounts that approximate what hospitals actually pay to acquire the drugs.”
Survey Requirements
On April 24, 2020, CMS released its Hospital Survey for Specified Covered Outpatient Drugs Average Acquisition Cost, as well as an instruction sheet providing context and information regarding the survey. The instruction sheet specifies that all hospitals that were enrolled in the 340B program in the last quarter of 2018 and/or the first quarter of 2019, excluding CAHs, are required to respond to the survey by May 15, 2020. CMS noted in the instruction sheet that covered entities must maintain accurate records documenting compliance with all 340B program requirements as a condition of participating in the 340B Drug Pricing Program, and therefore each hospital “should have readily available access to the data that is being requested via this survey.”
Contrary to what was previously reported in Federal Register and preliminary CMS survey documents, the final survey instrument offers two options: Hospitals can choose to either submit the quick survey or the detailed survey.
Both the detailed survey and quick survey require respondents to provide the following information:
Hospitals can choose to provide CMS no further information by submitting the quick survey, but by doing so, they will allow CMS to use the 340B ceiling prices obtained from the Health Resources and Services Administration as indicative of the hospital’s drug acquisition costs. After selecting this option, the survey is complete, but requires that the hospital make an affirmative representation to CMS that it acquires all 340B drugs at the 340B ceiling price. Such a statement may not be accurate for some hospitals.
Alternatively, hospitals may choose to submit the detailed survey, which requires the submission of the net acquisition cost for each specified covered outpatient drug acquired under the 340B program, i.e., the sub-ceiling price after all applicable discounts. This includes, but is not limited to, 340B drugs purchased via a replenishment model or under penny pricing. The 340B drug acquisition cost should be reported regardless of whether the drug was dispensed, or whether the drug was dispensed in multiple settings. If the acquisition cost for a specific drug reported in the detailed survey is unknown, CMS will use the 340B ceiling price as a proxy. Importantly, the detailed survey appears to only provide for reporting of the average acquisition cost of drugs when purchased through a 340B account, not the actual average acquisition cost of the drug at issue. Therefore, submission of the detailed survey information would only result in reporting of costs at or below the 340B ceiling price and does not provide a mechanism to account for the fact that many hospitals must purchase drugs for outpatient dispensing on non-340B accounts and at rates higher than the 340B ceiling price.
Detailed survey respondents must complete an Excel spreadsheet with the following information:
The survey instruction sheet provides several appendices, including an NCD-HCPCS crosswalk, two examples of how to calculate the average acquisition cost, specifically for HCPCS codes J-885 (Injection, epoetin alfa, (for non-esrd use), 1000 units), and J0878 (Injection, daptomycin, 1mg).
Hospitals with questions regarding the survey should contact the 340B Survey Technical Helpdesk Hotline at +1 833 886 5682. Hospitals should submit all survey responses to the applicable Medicare Administrative Contractor.
The survey does not clarify potential repercussions for failure to submit the survey instrument, and it remains unclear what authority CMS may rely on to enforce the reporting requirement.
Prior to using the data for future publications, including rulemaking, CMS must submit a report to OMB providing nonresponse bias and standard error analytical results. CMS must also describe any limitations in the generalizability of the information collected. This report from CMS could identify those hospitals that did not report data, potentially in a public-facing document.
Takeaways
CMS makes clear in the survey instructions that the purpose of the survey is to collect data necessary to establish “acquisition cost” payment rates for 340B drugs dispensed to hospital Medicare patients. Accordingly, it appears likely that CMS’s May 15, 2020, submission timeframe is intended to solicit the necessary information in order to propose acquisition cost-based payment rates for 340B drugs in the 2021 OPPS proposed rule (expected to be released in early July 2020) using the survey’s findings.
While it remains uncertain whether a court would agree that the survey meets the statutory requirements necessary to use the data for such purposes, if CMS is unsuccessful in its appeal of the prior 340B rate cuts, it is highly likely that CMS will use the data for both prospective rate cuts and possibly in connection with any remedies required for the prior rate cuts. Further, if the survey data reflects rates below the prior 22.5% rate cut, CMS could proceed with even more significant cuts to 340B payments.
Because the survey does not provide any mechanism to report 340B average acquisition costs above the 340B ceiling price, use of the survey for future rate setting would appear to result in a rate no higher than the 340B ceiling price. If a material number of hospitals use the detailed survey, it could result in Medicare rates for 340B hospitals at rates below the 340B ceiling price, notwithstanding that hospital outpatient drug costs may be much higher.
Although many hospitals are currently being challenged by COVID-19 response efforts, hospitals should nevertheless carefully consider whether to submit the quick survey or detailed survey, including evaluation of such issues as the resources required to complete the survey, potential for inaccurate statements of purchasing costs to CMS, impact to future rate setting and public disclosure of reported information.
ARTICLE / CLIENT ALERT
April 27, 2020
Read time: 7 min
On April 21, 2020, the US Department of Health and Human Services (HHS) Office of Inspector General (OIG) released a proposed rule that would amend its civil money penalty (CMP) regulations to address a 21st Century Cures Act amendment to the CMP Law (CMPL) authorizing HHS to impose CMPs, assessments and exclusions upon individuals and entities that engage in fraud and other misconduct related to HHS grants, contracts and other agreements (42 USC 1320a-7a(o)-(s)). OIG’s proposed rule would also address the Cures Act amendment to the Public Health Services Act (42 USC 300jj-52) authorizing OIG to investigate claims of information blocking and providing the Secretary of HHS authority to impose CMPs for information blocking, as well as Bipartisan Budget Act of 2018 increases to penalty amounts in the CMPL. The public will have at least 60 days to comment on OIG’s proposals, although OIG is monitoring requests to extend that period in light of the Coronavirus (COVID-19) public health emergency.
This On the Subject briefly outlines OIG’s proposal to implement the Cures Act CMP authorities for grant, contract and other agreement fraud or misconduct. We discuss OIG’s information-blocking-related proposals in a separate On the Subject.
The Basis for Liability
OIG proposes to add a new section 1003.700 that would list the new CMP offenses created by the Cures Act related to fraud and other misconduct involving grants, contracts and other agreements when a person, excluding a program beneficiary:
The statutory definition of “other agreement” under 42 USC 1320a-7a(q)(3) is quite broad, and contains a non-exclusive list of arrangements that could constitute “other agreements,” such as a scholarship, loan, subsidy, donation agreement, award and sub-award. OIG states that when deciding to impose sanctions, it will “evaluate each matter on a case-by-case basis to determine whether the funding arrangement at issue constitutes an “other agreement” under the statute and whether the conduct at issue violates the statute.”
As discussed in the preamble, OIG appears to view these statutory authorities as broadly expanding OIG’s CMP jurisdiction beyond federal healthcare programs, such as Medicare and Medicaid, to many other HHS programs, such as National Institutes of Health or Centers for Disease Control and Prevention grants or any number of contracts that HHS enters into to manage its programs. In the current COVID-19 environment, OIG may also view these authorities as applying to the Provider Relief Fund payments, which HHS is currently administering as a grant through the Health Resources and Services Administration.
The placement of this statute in the Social Security Act (SSA) (which governs the Medicare and Medicaid programs as well as grants to states for unemployment compensation and other programs and the Social Security income benefit) raises a question of how far these CMP authorities extend to other HHS programs that are not contained in the SSA. The Cures Act does not define “grant” or “contract” in its CMPL amendment, and neither does OIG in the proposed rule. The nature of the CMPL, including being part of the SSA, suggests that these CMPs could arguably be limited to the grants, contracts and other agreements governed by the SSA.
Penalties, Assessments and Exclusion
The proposed rule codifies the statutory penalties for each of the five offenses, which range from a maximum of $10,000 to $50,000 per offense, as measured by the applicable offense trigger (such as each claim, each false record or statement, or each day an overpayment is retained or access is not granted). OIG also may impose an assessment of not more than three times the amount involved with the improper conduct and may impose an exclusion from federal healthcare programs.
The Cures Act includes federal and state healthcare program exclusion as a potential consequence of offenses involving grants, contracts or other agreements. Federal and state healthcare program exclusion is consistent with the traditional scope of the CMPL as pertaining to offenses involving the federal healthcare programs. There is, however, a disconnect in providing for exclusion as a consequence for an offense that was not connected to federal or state healthcare programs for which an HHS debarment could apply. The proposed rule does not explain this issue further and does not explain under what circumstances exclusion would be considered.
Aggravating and Mitigating Factors
OIG’s proposed rule discusses, in terms similar to other CMP authorities, the aggravating and mitigating circumstances considered when determining the amount of penalties and assessments and the period of exclusion. The list of aggravating factors is not all-inclusive, and both the aggravating and mitigating factors largely mirror the factors related to the fraudulent or false submission of healthcare claims.
The proposed mitigating factor is if:
The proposed non-exclusive list of aggravating factors includes the following:
The proposed rule can be found here.
ARTICLE
April 27, 2020
Read time: 1 min

ARTICLE / CLIENT ALERT
April 27, 2020
Read time: 17 min
The requirement to stay at home is giving many of us the opportunity to undertake (or no excuse to ignore) the household and DIY tasks at home that have long been at the bottom of the to-do list. Similarly, directors, management teams and employees are adapting to the new normal of operating under lockdown and having taken steps to protect and stabilise their businesses. With social distancing restrictions extended in the United Kingdom until at least 7 May 2020, businesses may wish to use this time to do some corporate and business housekeeping.
Once businesses have focused on the challenges that the Coronavirus (COVID-19) pandemic presents, taken advantage of available government schemes and (where applicable) adapted products, services, facilities and distribution channels in response, they should refocus on their legal and business fundamentals. For example, now may be the perfect time to tidy up corporate structures, update compliance policies, reinvigorate Brexit contingency plans, and plan for upcoming legal and regulatory changes.
This could also be a prime opportunity to innovate. The lockdown poses a risk that businesses could stagnate, distracted by the disruption to operations and the imposition of remote working. However, this period may actually give some teams within your business the opportunity to revisit strategies, adapt business plans for the ever-changing market conditions and consumer needs, pipeline plan for potential M&A opportunities, develop new marketing campaigns and be ready to hit the ground running as and when restrictions are eased.
This article considers key fundamentals that businesses should ensure are not forgotten in the midst of the COVID-19 crisis, and also explores some of the ways that businesses can use the lockdown period to focus on new initiatives.
Corporate
General Housekeeping
Keep detailed board minutes – Directors cannot avoid the fact that decisions taken now could be scrutinised later with hindsight bias. However, they are considerably less likely to be challenged if full and accurate board minutes have been taken to help demonstrate how key issues were debated and considered, and the basis on which decisions were ultimately made.
Keep up with filings – The Financial Reporting Council, Financial Conduct Authority and Prudential Regulation Authority released joint guidance for companies and auditors to address the challenges that remote working may raise in this context. While deadlines for publication of annual accounts have been relaxed for both listed and unlisted companies, trying to make progress while in lockdown may allow teams to focus on driving the operational side of the business once lockdown measures are eased.
Potential Projects
Reorganisations and group simplifications – It is not unusual for dormant companies, redundant SPVs or holding companies to sit in group structures “for a rainy day”, or for there to be companies within the group that cause a dividend block. Now may be the time to tidy up the group structure and take away the headaches of audits and filings for dormant entities and redundant holding entities, and free up the group structure from a dividend perspective. If you have recently acquired businesses, it may be worth digging out due diligence reports to see whether there were any such issues that were flagged but which have not yet been addressed. Be aware that such reorganisations could require lender consent under your finance arrangements.
M&A
General Housekeeping
Key dates for SPA claims – While regulators may be granting companies more flexibility in terms of filing dates, sellers are not going to be so generous in terms of dates for submitting purchase price adjustment, warranty, indemnity and tax deed claims. Be mindful of expiring limitation periods, and spend time assessing the potential claims and gathering information to support such claims.
Focus on integration – In almost every model supporting an acquisition case, there will be a line item for synergies. While there may not currently be appetite for new acquisitions, time can be spent focusing on recent acquisitions to ensure that those synergy targets are achieved.
Potential Projects
Pipeline planning – While executing M&A in the current market may present challenges, M&A and corporate finance teams can use the time to undertake detailed desktop due diligence on potential targets. Planning the order in which a series of transactions may be carried out could help to avoid competition issues down the line. In addition, in the current market, now may be the time to test management’s and the investment committee’s appetite to look at distressed opportunities and to spend time getting a greater understanding of the nuances of distressed or insolvency-driven sale processes.
Prepare for future sales – An efficient sale process can help to ensure a seller obtains the best price. Now may be the time to dedicate internal resources to compiling a data room, preparing and verifying teasers and information memoranda, and producing vendor due diligence reports to develop a smooth process if there is an M&A bounce. Ensuring that intellectual property portfolios are in order and the databases are in good compliance with data protection and other laws is valuable preparation. It may be worth considering a refresh of ABC/AML and other compliance policies and manuals and looking to address any lingering defined benefit pension scheme issues.
Brexit
General Housekeeping
Amendments to contracts – If you are renegotiating contracts as a result of COVID-19-related issues, it may be worth considering whether any Brexit-related changes should be made at the same time. Such changes include (i) ensuring that definitions referring to EU derived statute are amended to refer to UK law; (ii) checking to see if any Change Control, Material Adverse Change clauses or Force Majeure clauses will be triggered by Brexit; (iii) where the contracts refer to European Trade Marks or European Registered Community Designs, these will lose protection in the UK and so details of the automatically generated corresponding new UK marks and designs should be added; (iv) reviewing the tax provisions to take account of changes to VAT, the Interest and Royalties Directive and any provisions allowing for the recovery of withholding tax on royalty payments; (v) analysing whether any suppliers or subcontractors are affected by Brexit; and (vi) for international contracts, consider whether alternative dispute resolution should be adopted whilst there is no automatic recognition of English judgements in the EU.
Potential Projects
Brexit contingency planning – When faced with the challenges and disruption caused by the COVID-19 pandemic, many businesses may have put Brexit-related planning on hold. Now that many businesses are adapting to the new normal, it may be worth reinvigorating this process. There will likely be many learnings that can be taken from the implementation of COVID-19 contingency measures.
Finance
General Housekeeping
Maintain regular contact with lenders – Maintaining regular contact with your finance providers is particularly important in times of economic uncertainty. Banks will take comfort from a regular dialogue and will be more likely to support businesses where they trust the management team is being open with them.
Potential Projects
Review existing facilities and explore options – Any requests for new money on deals may be challenging at the moment, but consider the reallocation of existing tranches of cash under facility agreements. Can you agree with your lender to re-purpose an existing capex line? Are there any reserves that can be released or discussions that can be had with lenders to agree that those reserves can be used for a specific purpose? It is worth reviewing your existing facilities to see what might be possible. Whatever you might want to do, bear in mind that even if a positive response can be obtained from a lender, it is likely to take quite some time to get the necessary credit committee approvals from your existing lender, even if the request makes perfect sense. We are all facing similar challenges with the usual day-to-day working, and lenders are no exception.
Prepare for potential equity fundraisings – For listed companies, the Pre-Emption Group’s relaxation of its guidance on non-pre-emptive offers may make it worth exploring whether existing shareholders would be willing to support the business by injecting equity through a cashbox placing. Alternatively, if it looks like a larger fundraising may be required, now may be the time to start discussions with your financial advisers and kick off the process for producing an initial draft of a prospectus. Private companies may also want to engage with their advisers in relation to exploring private placements with existing and new shareholders.
Intellectual Property
General Housekeeping
Patent strategy – The much-anticipated Unitary Patent is now very unlikely to cover the United Kingdom as the UK Government is not willing to accept the supremacy of a European court. As a result, businesses’ UK patents strategy will need to be adapted to ensure new patents are obtained as part of any European or global patent strategy. Any infringement claims should also treat the United Kingdom as an additional jurisdiction.
Potential Projects
Licence and agreement review (trade marks) – From the end of the Brexit transition period, EU Trade Marks and UK Registered Community Designs will no longer include the United Kingdom, which may cause unintended effects in licences and agreements. Holders of EU Trade Marks or UK Registered Community Designs will be automatically granted additional trademarks or designs from the UK Intellectual Property Office. However, businesses may want to use this time to (i) review existing licences and agreements to ensure they still work for the business (e.g., is the geographical scope accurate post-Brexit, and do indemnities for third-party IP infringement still cover the right territories?), and (ii) ensure that these new intellectual property rights are reflected in all future agreements. The rules relating to the international exhaustion of trade marks when products are first put into the market will also change. Consequently, a business that sells products in both the United Kingdom and the European Union should consider the effect this change could have on its distribution strategy and pricing.
Human Resources
General Housekeeping
Review template contracts of employment and engagement – Over time, precedent contracts become out of date and can lose integrity as a result of ad hoc amendment. Conducting a wholesale contract review is a job that businesses often place on the “to do” list but rarely have time to complete. This is a particularly good time to take on this task, in light of recent changes to the legal requirement that employers provide employees with a written statement of employment particulars (sometimes called a section 1 statement) and the extension of that requirement to workers.
Review internal policies – This is another task that is important but time consuming. Policies should be reviewed regularly to ensure continuing compliance with laws and best practice. For example, over the past few years, our understanding of how holiday and holiday pay should operate has changed. Employers have had to react quickly to the changes. Now is the time to consider how holiday will be addressed and accommodated on an ongoing basis. It is important to review the policies as a whole, to identify any areas of inconsistency between them, and to ensure that it is clear which policies (or sections thereof) are intended to have contractual effect and which do not.
Potential Projects
Homeworking – The current crisis may change how we work going forward. Now is the time to consider how your business could adapt. Could long-term homeworking be accommodated? If so, what are the pros and cons? If employees wanted to work from home, is your homeworking policy fit for purpose? What equipment would employees need? Employees may raise the issue of changing the way that they work as soon as lockdown is eased (as some may not want to rush back onto crowded public transport). Therefore, it would be useful to have done this thinking beforehand.
Return to Work – At some point, lockdown will be eased and employees will be able to return to the workplace. However, some social distancing recommendations may remain in place, and employees may generally have a heightened sensitivity to working in close confines with others. Consider in advance how your workplace might be able to accommodate these issues and demonstrate to employees that you are alive to their concerns. For example, are there changes that could be made to the work environment, or to the pattern of working? Do any kitchen facilities meet high hygiene standards?
Data Protection and Privacy
General Housekeeping
Record keeping and accountability – As we near the two-year anniversary of the General Data Protection Regulation’s (GDPR) entry into force, now is a good time to take stock of compliance efforts to date. A key part of the GDPR is record keeping and this includes insuring that data protection impact assessments (DPIAs) have been and continue to be undertaken for all high-risk processing activities. Many of the Data Protection Authorities are now permitting a lower standard of data protection compliance and a regime of lesser enforcement. The open questions are first, what lower standard of compliance should be adopted and second, what should be done after the pandemic when this relaxation by the regulators is reversed? A DPIA is a great tool for helping to determine and to document the lower standard of compliance that is adopted. Secondly, its inherent record keeping allows a company to effectively track the areas of relaxed compliance so that they can be addressed post pandemic. However, as a note of caution, although the regulators are adopting a lower standard, a court may not adopt a similar approach in any privacy law suit against the company. DPIA’s will again provide a helpful evidential trial to show that due consideration was given to the companies responsibilities and data subject’s rights.
Update data protection notices and policies – Data protection notices and policies should be reviewed regularly to ensure continuing compliance with laws and evolving regulatory guidance. Since the entry into force of the GDPR and the regulator’s response to the Covid-19 pandemic, a substantial amount of regulatory guidance has been released both at the EU level and at the Member State level. With the changes to the way of doing work, particularly with the adoption of remote working – many data protection notices and polices should now be updated.
Potential Projects
International data transfer strategy (EU-UK data flows) – After the end of the Brexit transition period, on 31 December 2020, in the absence of an EU Commission adequacy decision, businesses must ensure that all EU-UK data flows continue to comply with applicable data protection requirements after the end of the transition period. A strategy will be needed, in both the short and long term, to manage these international data flows. Consider whether standard contractual clauses offer sufficient coverage in the long term or whether binding corporate rules would offer the most robust long-term solution. Now is a good time to get ahead of this issue.
IT and Cybersecurity
General Housekeeping
Increase in social engineering, ransomware and other exploits – The incidence of the Covid-19 pandemic has brought with it an expected flood of increased hacking activity. With employees moving to remote working, there are now many more ways in which hackers can gain access to company systems. These range from an increase in phishing emails on Covid-19 related topics, fake approaches by the firm’s IT “help desk”, third party “support” to help fix home internet or router problems or technical exploits arising from insecure home WiFi or routers. Consider whether the IT security policy suite appropriately covers remote working. Typically, it may be necessary to update remote working policies and “bring your own device” policies, and to make adjustments to any breach response policy. Consider also if any heightened IT system monitoring will be enabled for employees working from home. All of these issues will have considerable data protection and employment considerations, as well as IT policy considerations.
Cyber incidence response – This greater likelihood of breaches means that it is important to have an effective cyber incidence or breach response plan. These plans should be adapted to take into account remote working and remote detection. Third parties who will assist in the response, cyber investigators, PCI Forensic Investigators, lawyers, insurers, and PR companies should be identified and retained in a way so that they can get to work quickly. Timescales for data breach reporting to regulators and affected individuals should be understood, as this can now be as low as 2 hours for companies subject to the Payment Services Directive No. 2. Finally, with the greater likelihood of follow on class actions or other litigation, care should be taken that the correct rules are followed with regard to document preservation and legal and litigation privilege, so that certain reports can be protected from disclosure to third parties.
Potential Projects
Third-party commercial contract review – Review IT supply and IT outsourcing agreements to ensure that these contain the mandatory language prescribed by Article 28 GDPR. Failure to include this language amounts to a breach of the GDPR and exposes businesses to unnecessary commercial risk. Brexit will also have an impact on IT agreements. In addition to the steps mentioned above, to mitigate risk companies should review indemnities providing protection for high-risk IT liabilities such as GDPR to ensure they are effective for both UK GDPR and EU GDPR risks.
Real Estate
General Housekeeping
Landlords – Landlords should review existing leases and consider whether any specific provisions protecting landlords/tenants should (or should not) be inserted in relation to future pandemics such as this one. Where tenants are not paying rent, landlords should assess whether they can secure such rental streams (e.g., by claiming on existing rent deposits), and should assess what points should be considered in this regard, such as potential top-up rights. Developer landlords dealing with ongoing projects may wish to review guidance on force majeure and other terms which potentially allow for construction contracts to be terminated, should the need arise, or alternatively in order to strengthen the developer’s position in advance of commercial discussions with such contractors.
Tenants – Tenants are advised to assess ongoing rent liabilities and other costs (e.g., by taking immediate action to reduce rent and other financial liabilities). The moratorium on forfeiture for non-payment of rent under the Coronavirus Act 2020 offers tenants some protections, but is a cash-flow aid only. Rent (plus interest) remains fully payable as of 30 June 2020. In addition, tenants may wish to look at their existing utility contracts, especially in buildings that are largely unoccupied due to COVID-19, to see whether services can be suspended or terminated.
Potential Projects
Portfolio reviews – Real estate owners and investors could consider reviewing their portfolios in light of the COVID-19 crisis, for example by looking to invest in sectors which are likely to thrive in the “new world” post-COVID-19 (such as residential, multi-family, logistics) or alternatively picking up assets in more distressed sectors at suitably low prices. Some property owners could look to reposition their existing assets in line with the developing market—for example, retail space being redeveloped into warehousing or affordable housing units. Certainly it is a time for all property holding companies and real estate investors to revisit existing business strategies, look into repositioning defunct or under-performing assets, and reboot commercial and strategic thinking where necessary. In terms of reopening for business after the pandemic is over, owners and operators of assets in the more affected sectors (e.g., hotels) would be well advised to produce checklists going forward, for example on any regulatory requirements which need to be fulfilled in order to reopen.
Tax
General Housekeeping
The last few years have seen a series of major changes to the corporate tax regime in the United Kingdom and elsewhere, and many taxpayers may understandably have struggled to keep up. The United Kingdom introduced significant limitations on the deductibility of interest, a new tax charge on offshore intellectual property that is exploited in the United Kingdom, new restrictions on loss carry-forwards, and anti-hybrid rules. None of these were grandfathered, and all potentially could render formerly tax-efficient structures significantly less beneficial. Internationally, governments have moved to close down tax “treaty-shopping” opportunities and to ensure that intra-group transactions are underpinned by substance. Now may be a good time to review whether historic structures remain fit for purpose.
Potential Projects
Following the COVID-19 outbreak, the UK Government postponed changes to the IR35 rules, which would require large and medium-sized businesses to assess whether contractors engaged through personal service companies should be regarded as employees for tax purposes (with consequent PAYE obligations). Even before the lockdown, there were significant concerns that business had not had sufficient preparation time to administer and comply with the new rules effectively. The delay until April 2021 will allow many underprepared businesses to undertake a proper review of their contractors and to ensure that they are fully compliant.

ARTICLE
April 24, 2020
Read time: 2 min
The Coronavirus (COVID-19) pandemic is bringing unprecedented disruption to the private M&A market. Even in today’s uncertain environment, however, certain deals are still moving forward. To usher existing agreements to successful completion and seize opportunities in today’s—and tomorrow’s—market, sellers and buyers alike need to carefully calibrate their deal terms in a fast-changing landscape.
In this deck, we take a closer look at strategies for due diligence and process, techniques for bridging valuation gaps and protecting value, key issues for representations and warranties, trends in interim covenants, and much more.
Interested in a webinar on this topic? Let us know what you are most interested in by filling out this survey.
Learn more on COVID-19’s impact on mergers and acquisitions in this recently published Forbes article “The Impact of the Coronavirus Crisis on Mergers & Acquisitions” co-authored by David Lipkin. In this article, he discusses how the foregoing factors and others have already impacted M&A dealmaking and will likely continue to impact the M&A world for some time to come.
For more resources relating to COVID-19, please visit McDermott’s Coronavirus Resource Center, brought to you by a multi-disciplinary team. Our site will keep you informed of the latest developments and provide comprehensive insight to help you navigate this crisis.

ARTICLE / CLIENT ALERT
April 23, 2020
Read time: 5 min
Seventh in a series of updates on how the pandemic is informing basic elements of governance.
The extraordinary pandemic-based financial challenges impacting hospitals, health systems and other providers as a result of the Coronavirus (COVID-19) should prompt boards to re-evaluate focus on their duty to monitor the organization’s financial condition. Existing case law provides useful direction on the scope of these duties, particularly during periods of financial distress. There is value to enhancing the engagement of the board’s finance (or similar) committee on solvency matters during this period of crisis.
Of course, the corporation’s business and day to day operational performance are managed under the oversight of the board of directors. More specifically, the board is expected to focus on the integrity and clarity of the company’s financial reporting and other disclosures about corporate performance. The board is also expected to have meaningful involvement in the company’s capital allocation process and strategy, and in reviewing, understanding and overseeing annual operating plans and budgets.
These responsibilities expand as the corporation experiences material financial distress and approaches potential insolvency. Old concepts of “the zone of insolvency” have been rejected by many courts. However, case law does recognize a shift in the identity of to whom the board’s duties run.
Generally speaking, the fiduciary duties of directors of solvent companies run to the shareholders (in the case of for profit companies) and to the corporate mission (in the case of not-for-profit corporations). Should the company become insolvent, however, those duties may be extended to the creditors of the company, as well due to their equitable interests in the company at that point in time. As a result, creditors may be able to pursue derivative claims based on allegations of breach of fiduciary duties owed to the totality of the company’s claimants (including its creditors).
This doesn’t mean, however, that when a company enters insolvency its directors must pursue certain creditor-focused extraordinary actions. Directors are able to act consistent with informed business judgment to pursue corporate strategies that reflect the best interests of all of the residual claimants. In other words, fiduciary duties are owed to the enterprise itself rather than any particular stakeholder.
Of course, the impact of the pandemic has had a disastrous financial impact on hospitals, health systems, physician groups and other providers, arising primarily from the suspension of normal operations due to restrictions on scheduled or non-emergent procedures. In many instances, the steep declines these providers are experiencing in volume and revenue raise questions as to whether they are either approaching insolvency or have actually become insolvent.
Courts have defined “insolvency” under both a balance sheet test and a cash flow test. Under the balance sheet test, a company is insolvent if the sum of its debts exceed the aggregate value of its assets. A company is insolvent under the cash flow test if it is unable to pay its debts as they become due.
Fiduciary issues may arise even in circumstances where the actual or potential insolvency is expected to be only temporary. Creditors may pursue breach of duty claims as long as the insolvency existed at the time of the alleged breach and the plaintiff was a creditor of the company at that time.
In this time of crisis, the board, its finance committee and its financial officers should be alert to the warning signs of insolvency. They should also be particularly attentive to the proper exercise of their fiduciary obligations (including the avoidance of material board-level conflicts of interest) to the extent they could be perceived as damaging to the interests of creditors. It is important to remember that it is difficult to determine when a company may become insolvent, and any cause of action will be brought with the benefit of hindsight.
Case law suggests that a creditor will have a difficult time obtaining judgment on a derivative claim for breach of fiduciary duty during a time when the company was insolvent. But, these claims often follow a notoriously slow pace through the courts. Directors and financial officers should thus be mindful of the old saying that “you may avoid the result, but you will not avoid the ride.” For this and other reasons, proper planning by the finance committee can be critical.
Click here to access the first article in this series, Corporate Authority for Extraordinary Delivery of Care Decisions.
Click here to access the second article in the series, The Executive Committee in Times of Crisis.
Click here to access the third article in the series, Virtual Board Meetings in Times of Crisis.
Click here to access the fourth article in the series, Emergency State Action Affecting Board Processes and Corporate Filings.
Click here to access the fifth article in the series, Assuring Appropriate Information Flow to the Risk and Compliance Committees.
Click here to access the sixth article in the series, Revisiting Executive and Board Succession Planning in Response to the Pandemic.